XML 70 R12.htm IDEA: XBRL DOCUMENT
v2.4.0.8

4. Intangible Assets, Goodwill and Other | 12 Months Ended
--- | ---
Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets Disclosure | 4. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS Changes to goodwill by segment were as follows (in millions):
|  | 2013 |  |  | 2012
|  | Life Science |  | Clinical Diagnostics |  | Total |  |  | Life Science |  | Clinical Diagnostics |  | Total
Balances as of January 1: |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  | $ | 193.6 |  |  | $ | 330.0 |  |  | $ | 523.6 |  |  |  | $ | 176.8 |  |  | $ | 319.3 |  |  | $ | 496.1 |
Accumulated impairment losses and write-offs |  | (27.2 | ) |  | (1.0 | ) |  | (28.2 | ) |  |  | (27.2 | ) |  | — |  |  | (27.2 | )
Goodwill, net |  | 166.4 |  |  | 329.0 |  |  | 495.4 |  |  |  | 149.6 |  |  | 319.3 |  |  | 468.9 |
Acquisitions |  | 14.9 |  |  | — |  |  | 14.9 |  |  |  | 17.4 |  |  | 4.1 |  |  | 21.5 |
Purchase adjustment |  | — |  |  | — |  |  | — |  |  |  | (0.6 | ) |  | — |  |  | (0.6 | )
Goodwill written off related to excess property |  | — |  |  | — |  |  | — |  |  |  | — |  |  | (1.0 | ) |  | (1.0 | )
Currency fluctuations |  | 0.5 |  |  | 7.0 |  |  | 7.5 |  |  |  | — |  |  | 6.6 |  |  | 6.6 |
Balances as of December 31: |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  | 209.0 |  |  | 337.0 |  |  | 546.0 |  |  |  | 193.6 |  |  | 330.0 |  |  | 523.6 |
Accumulated impairment losses and write-offs |  | (27.2 | ) |  | (1.0 | ) |  | (28.2 | ) |  |  | (27.2 | ) |  | (1.0 | ) |  | (28.2 | )
Goodwill, net |  | $ | 181.8 |  |  | $ | 336.0 |  |  | $ | 517.8 |  |  |  | $ | 166.4 |  |  | $ | 329.0 |  |  | $ | 495.4 |
In conjunction with the acquisition of 100% of the outstanding shares of AbD Serotec in our Life Science segment in January 2013, we recorded $14.9 million of goodwill and $44.0 million of definite-lived intangible assets: $33.0 million of developed product technology, $8.8 million of licenses, $1.3 million of customer relationships/lists, $0.4 million of tradenames and $0.5 million of other purchased intangibles. The weighted average useful lives of the definite-lived intangible assets as of the acquisition date were 13.9, 13, 12, 2 and 1 years, respectively, with a total weighted average useful life of 13.7 years. In December 2012, we sold a building for $6.4 million in our Clinical Diagnostics segment that was associated with a 1999 acquisition. We recognized a gain on the sale of $4.3 million and a portion of the goodwill recorded in a 1999 acquisition was written off of $1.0 million. In conjunction with the purchase of certain assets from Propel Labs, Inc. in our Life Science segment in August 2012, we recorded $17.4 million of goodwill and $32.1 million of definite-lived intangible assets: $27.3 million of developed product technology, $4.7 million of covenants not to compete and $0.1 million of other intangible assets. In conjunction with the acquisition of 100% of the outstanding shares of DiaMed Benelux in our Clinical Diagnostics segment in July 2012, we recorded $3.0 million of goodwill and $4.9 million of definite-lived intangible assets: $3.8 million of customer relationships/lists and $1.1 million of tradenames. In conjunction with the acquisition of certain assets from a raw material supplier in our Clinical Diagnostics segment in January 2012, we recorded $1.1 million of goodwill and $5.1 million of definite-lived intangible assets considered developed product technology. Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
| December 31, 2013
| Average Remaining Life (years) |  | Purchase Price |  | Accumulated Amortization |  | Net Carrying Amount
Customer relationships/lists | 1-11 |  | $ | 99.8 |  |  | $ | (41.1 | ) |  | $ | 58.7 |
Know how | 2-12 |  | 194.6 |  |  | (89.3 | ) |  | 105.3 |
Developed product technology | 1-13 |  | 109.5 |  |  | (36.2 | ) |  | 73.3 |
Licenses | 1-12 |  | 44.9 |  |  | (22.4 | ) |  | 22.5 |
Tradenames | 1-9 |  | 4.3 |  |  | (2.1 | ) |  | 2.2 |
Covenants not to compete | 5-9 |  | 4.9 |  |  | (0.7 | ) |  | 4.2 |
Other | — |  | 0.6 |  |  | (0.6 | ) |  | — |
|  |  | $ | 458.6 |  |  | $ | (192.4 | ) |  | $ | 266.2 |
| December 31, 2012
| Average Remaining Life (years) |  | Purchase Price |  | Accumulated Amortization |  | Net Carrying Amount
Customer relationships/lists | 1-12 |  | $ | 102.8 |  |  | $ | (38.4 | ) |  | $ | 64.4 |
Know how | 1-13 |  | 189.3 |  |  | (67.1 | ) |  | 122.2 |
Developed product technology | 1-10 |  | 74.6 |  |  | (25.1 | ) |  | 49.5 |
Licenses | 1-8 |  | 35.6 |  |  | (18.7 | ) |  | 16.9 |
Tradenames | 1-10 |  | 7.4 |  |  | (4.3 | ) |  | 3.1 |
Covenants not to compete | 1-10 |  | 4.9 |  |  | (0.2 | ) |  | 4.7 |
Other | 1 |  | 0.1 |  |  | — |  |  | 0.1 |
|  |  | $ | 414.7 |  |  | $ | (153.8 | ) |  | $ | 260.9 |
No material impairment losses related to intangible assets were recorded in 2013 or 2012. Amortization expense related to purchased intangible assets for the years ended December 31, 2013, 2012 and 2011 was $45.0 million, $42.8 million and $39.1 million, respectively. Estimated future amortization expense (based on existing intangible assets) for the years ending December 31, 2014, 2015, 2016, 2017, 2018 and thereafter is $42.0 million, $39.0 million, $35.6 million, $27.0 million, $24.1 million, and $98.5 million, respectively.

X
- Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13854-109267 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration